期刊文献+

冠心病心绞痛患者血浆高敏C反应蛋白和基质金属蛋白酶-9变化及其临床意义 被引量:3

The alteration and significance of plasma high sensitivity C-reactive protein and matrix metalloproteinase-9 in the patients with coronary heart disease
下载PDF
导出
摘要 目的探讨高敏C反应蛋白(hsCRP)及基质金属蛋白酶-9(MMP-9)在冠心病心绞痛发病机制中的作用。方法选择冠状动脉造影确诊的冠心病患者70例,分为稳定型心绞痛(SAP)组33例,不稳定型心绞痛(UAP)组37例,30例冠状动脉造影正常者作为对照组。分别采用免疫浊度法和酶联免疫吸附法检测血浆hsCRP、MMP-9水平。结果 UAP组血浆hsCRP、MMP-9水平为(2.95±0.62)mg/L、(24.29±4.73)mg/L显著高于SAP组的(1.83±0.57)mg/L和(19.83±4.63)mg/L(P<0.01),两组hsCRP、MMP-9均明显高于对照组(1.53±0.45)mg/L、(16.21±4.17)mg/L(P<0.05或P<0.01)。结论炎症介质在冠心病的发病过程中可能发挥重要作用,血浆hsCRP与MMP-9在反映冠状动脉斑块稳定性及冠状动脉病变的严重程度方面有重要的临床意义。 Objective To explore the role of high sensitivity C-reactive protein(hsCRP) and matrix metalloproteinase-9(MMP-9) in the mechanism of patients with coronary heart disease(CHD).Methods 70 patients with diagnosed as angina pectoris by coronary angiography were selected,among which there were 33 cases with stable angina patients(SAP group),37 cases with unstable angina pectoris(UAP group).At the same time,30 cases with normal coronary angiography were selected as control group.The level of hsCRP and MMP-9 were measured by immunonephelometry and enzyme-linked immunosorbant assay(ELISA),respectively.Results The mean plasma levels of hsCRP and MMP-9(2.95±0.62)mg/L,(24.29±4.73)mg/L in UAP group were significantly higher than those(1.83±0.57)mg/L,(19.83±4.63)mg/L of SAP group(P 0.01),and both were higher than those of control group(1.53±0.45)mg/L,(16.21±4.17)mg/L(P 0.05 or P 0.01).Conclusion Inflammatory mediators might play an important role in the pathogenesis of CHD,hsCRP and MMP-9 can reflect the stability of atherosclerotic plaque and the severity of coronary artery disease.
出处 《中国医药导报》 CAS 2013年第1期58-59,共2页 China Medical Herald
关键词 冠心病 心绞痛 高敏C反应蛋白 基质金属蛋白酶-9 Coronary heart disease Angina pectoris High sensitivity C-reactive protein Matrix metalloproteinase-9
  • 相关文献

参考文献9

  • 1Rodondi N,Marques-Vidal P,Butler J. Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults[J].American Journal of Epidemiology,2010,(05):540-549.doi:10.1093/aje/kwp428.
  • 2Davis NE. Atherosclerosis-an inflammatory process[J].Journal of Insurance Medicine,2005,(01):72-75.
  • 3Noto D,Cottone S,Cefalu BA. Inteleukin 6plasma levels predict with high sensitivity and specificity coronary stenosis detected by coronary angiography[J].Thrombosis and Haemostasis,2007,(06):1362-1367.
  • 4Yamamoto D,Takai S. Pharmacological implications of MMP-9 inhibition by ACE inhibitors[J].Current Medicinal Chemistry,2009,(11):1349-1354.doi:10.2174/092986709787846514.
  • 5Wang HR,Li JJ,Huang CX. Fluvastatin inhibits the expression of tumer necrosis factor-alpha and activation of nuclear factor-kappaB in human endothelial cells stimulated by C-reactive protein[J].Clinica Chimica Acta,2005,(1-2):53-60.
  • 6Nurkic J,Ljuca F,Nurkic M. Biomarkers of plaque instability in acute coronary syndrome patients[J].Medicinski Arhiv,2010,(02):103-106.
  • 7Pasqui AL,Renzo M,BovaG. Pro-inflammatory/anti-inflammatory cytokine imbalance in acute coronary symdromes[J].Clinical and Experimental Medicine,2006,(01):38-44.
  • 8Smeglin A,Frishman WH. Elastinolytic matrix metalloproteinases and their inhibitors as therapeutic targets in atherosclerotic plaque instability[J].Cardiology in Review,2004,(03):141-150.doi:10.1097/01.crd.0000105000.46909.81.
  • 9Kulach A,Dabek J,Glogowska-Ligus J. Effects of standard treatment on the dynamics of matrix metalloproteinases gene expression in patients with acute coronary syndromes[J].PHARMACOLOGICAL REPORTS,2010,(06):1108-1116.

同被引文献43

  • 1张玖文.复方丹参滴丸治疗冠心病心绞痛疗效观察[J].中药与临床,2012,3(4):39-40. 被引量:5
  • 2李静,常改.西雅图量表测量冠心病患者生活质量的评价[J].中国公共卫生,2004,20(5):594-594. 被引量:117
  • 3周宪梁,孙凯,李昭晖,孙莉,邹玉宝,惠汝太.基质金属蛋白酶与动脉粥样硬化斑块发生、发展的关系[J].中国比较医学杂志,2006,16(12):705-709. 被引量:11
  • 4Johnson JL.Matrix metalloproteinases:influence on smooth muscle cells and atherosclerotic plaque stability[J].Expert Rev Cardiovasc Ther,2007;5(2):265-82.
  • 5Back M,Ketelhuth DF,Agewall S.Matrix metalbproteinases in atherothrombosis[J].Prog Cardiovasc Dis,2010;52(5):410-28.
  • 6Shiomi M,Ho T,Hirouchi Y,et al.Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins[J].Atherosclerosis,2001;157(1):75-84.
  • 7van Bussel BC,Schouten F,Henry RM,et al.Endothelial dysfunction and low-grade inflammation are associated with greater arterial stiffness over a 6-year period[J].Hypertension,2011;58(4):588-95.
  • 8Wang LY,Tang JY,Liu J,et al. Dynamic changes in phe-notypic groups in patients with stable angina pectoris aftertreatment with xinxuekang capsule : a randomized con-trolled trial [J]. Curr Vase Pharmacol,2015,13(4) :492-503.
  • 9Xiong XJ,Wang Z,Wang J. Innovative strategy in treat-ing angina pectoris with chinese patent medicines bypromoting blood circulation and removing blood stasis :experience from combination therapy in Chinesemedicine [J]. Curr Vase Pharmacol,2015,13(4) :540-553.
  • 10郭冀珍.阿罗洛尔——无代谢不良反应的肾上腺素β受体阻滞药[J].中国新药与临床杂志,2008,27(4):313-316. 被引量:13

引证文献3

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部